Nab-paclitaxel + Carboplatin

Phase 2Small molecule

Nab-paclitaxel + Carboplatin is one of 85 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Triple-Negative Breast CancerActive, not recruiting

Non-Small Cell Lung CancerNot yet recruiting

Breast CancerActive, not recruiting

Triple-Negative Breast CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Not yet recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Trodelvy

Gilead

Preclinical

37 3

Megace

Bristol-Myers Squibb

Preclinical

4 4

Nab-paclitaxel + Carboplatin

AstraZeneca

Phase 2

1 5

Spravato

WWim Janssens

Preclinical

2 6

Nubain

AAultman Health Foundation

Preclinical

1 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 10

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Breast Cancer

NCT04138719

Q3 2028

Phase 2Recruiting

Triple-Negative Breast Cancer

NCT04159142

Q4 2029

Phase 1Not yet recruiting

Non-Small Cell Lung Cancer

NCT07699757

Q4 2040

Phase 2/3Not yet recruiting

Non-Small Cell Lung Cancer

NCT07365319

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Not yet recruiting·EEikon Therapeutics·Phase 2/3·NCT07365319·750 enrolled

Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HSK41959 Tablets in Combination With Standard Therapy in Patients With MTAP Deletion Locally Advanced or Metastatic Solid Tumors

Not yet recruiting· Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.·Phase 1·NCT07699757·258 enrolled

Breast Cancer1 trial

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT04138719·520 enrolled

Triple-Negative Breast Cancer1 trial

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT04159142·414 enrolled

Advanced Solid Tumors1 trial

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02658214·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Nab-paclitaxel + Carboplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nab-paclitaxel + Carboplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nab-paclitaxel + Carboplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

Nab-paclitaxel + Carboplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2028

Q4 2029

Q4 2040

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Breast Cancer1 trial

Triple-Negative Breast Cancer1 trial

Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News